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ABSTRACT
Objective: To evaluate survival impact of low anterior resection (LAR) in patients with 
epithelial ovarian cancer (EOC) grossly confined to the pelvis.
Methods: We retrospectively reviewed 397 patients who underwent primary staging surgery 
for treatment of 2014 International Federation of Gynecology and Obstetrics (FIGO) stage 
II–IIIA EOC: 116 (29.2%) IIA, 212 (53.4%) IIB, and 69 (17.4%) IIIA. Patients with grossly 
enlarged retroperitoneal lymph nodes positive for metastatic carcinoma were excluded. Of 
92 patients (23.2%) with gross tumors at the rectosigmoid colon, 68 (73.9%) underwent 
tumorectomy and 24 (26.1%), LAR for rectosigmoid lesions. Survival outcomes between 
patients who underwent tumorectomy and LAR were compared using Kaplan-Meier curves.
Results: During the median follow-up of 55 months (range, 1–260), 141 (35.5%) recurrences 
and 81 (20.4%) deaths occurred. Age (52.8 vs. 54.5 years, p=0.552), optimal debulking 
(98.5% vs. 95.0%, p=0.405), histologic type (serous, 52.9% vs. 50.0%, p=0.804), FIGO stage 
(p=0.057), and platinum-based adjuvant chemotherapy ≥6 cycles (85.3% vs. 79.2%, p=0.485) 
were not different between groups. No significant difference in 5-year progression-free 
survival (PFS; 57.9% vs. 62.5%, p=0.767) and overall survival (OS; 84.7% vs. 63.8%, p=0.087), 
respectively, was noted between groups. Postoperative ileus was more frequent in patients 
subjected to LAR than those who were not (4/24 [16.7%] vs. 11/373 [2.9%], p=0.001). The 
5-year PFS (60.3% vs. 57.9%, p=0.523) and OS (81.8% vs. 87.7%, p=0.912) between patients 
who underwent tumorectomy and those who did not were also similar.
Conclusion: Survival benefit of LAR did not appear to be significant in EOC patients with 
grossly pelvis-confined tumors.
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INTRODUCTION
Optimal debulking surgery is the most important factor for improving survival outcomes 
in patients with advanced or recurrent epithelial ovarian cancer (EOC) [1]. Extensive 
intraperitoneal seeding to the neighboring pelvic viscera often results in the need for 
rectosigmoid resection to achieve optimal debulking. The technique of low anterior resection 
(LAR) of pelvic tumor, adjacent rectosigmoid colon, and pelvic peritoneum with primary 
anastomosis has already been described by many surgeons, with acceptable associated 
morbidity in advanced or recurrent EOC [2,3].
Unlike in advanced or recurrent EOC, the salutary value of these practices in early-stage 
EOC confined to the pelvis is still questionable. A number of surgeons performed LAR 
for all rectosigmoid lesions without exception and irrespective of invasion depth or size of 
tumor. Although patients without gross residual tumor after LAR can have better prognosis, 
increased operation-related morbidity after LAR has also been reported in several studies 
[4-7]. Disruption of the anastomosis leading to clinical anastomotic leak is among the most 
troublesome complications after LAR. Anastomotic leak is associated with considerable 
morbidity, including impaired long-term functional outcome, and increased mortality. 
Several studies have found that prolonged operating time and blood-product transfusion were 
important factors associated with anastomotic leak. Thus, if the tumor infiltrating up to the 
serosa and subserosa of the rectosigmoid colon can be removed by only tumorectomy without 
gross residual tumor, the surgeons can possibly avoid unnecessary LAR in early-stage EOC. 
However, the oncologic safety of omitting LAR without compromising survival outcomes in 
early-stage EOC must be first established before the current practice patterns can be changed.
Until now, to the best of our knowledge, no studies have investigated the survival impact and 
safety of LAR in patients with early-stage EOC. Therefore, with this multicenter retrospective 
study, we aimed to evaluate the survival outcomes in patients with EOC grossly confined to 
the pelvis according to the methods of bowel surgery (tumorectomy vs. LAR). In addition, the 
survival outcomes between the patients who did not undergo any bowel surgery and those 
who underwent tumorectomy were compared to evaluate the prognostic implication of the 
resectional base after tumorectomy. The incidences of operation-related morbidity between 
patients who underwent LAR and those who did not were also compared.
MATERIALS AND METHODS
1. Patient cohort
The cohort under study was retrospectively recruited from 5 independent institutions. The 
study protocol was revised and accepted by each institutional ethics committees. We reviewed 
the medical records of 397 patients who underwent primary staging surgery for EOC between 
March 1990 and September 2015. All eligible patients were diagnosed as International 
Federation of Gynecology and Obstetrics (FIGO) stage IIA to IIIA by gynecologic pathologists 
of each institutions after staging surgery. Patients with grossly enlarged retroperitoneal 
lymph nodes proven positive for metastatic carcinoma were excluded.
Staging surgery included peritoneal washing cytology, total hysterectomy, bilateral salpingo-
oophorectomy, pelvic lymph node dissection, paraaortic lymph node dissection, and 
infra/supracolic omentectomy. Additional biopsy for suspicious lesions according to the 
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surgeons' discretion was allowed. Tumorectomy for rectosigmoid lesions was performed 
by gynecologic oncologists or colorectal surgeons with each institution's policy. LAR was 
routinely performed by colorectal surgeons in each institution as follows: 1) The superior 
rectal vessel was ligated above the extent of the pelvic disease after the retrorectal space 
was developed; 2) The rectosigmoid colon was divided below the peritoneal reflection and 
approximately 7 cm above the anal verge; 3) The rectosigmoid colon was resected with a 
gastrointestinal anastomotic stapler in most patients; 4) End-to-end anastomosis (EEA) 
was performed with an EEA stapler. Unlike in the routine procedure, the inferior mesenteric 
artery was not sacrificed, except when mobilization of the distal bowel was necessary to allow 
tension-free anastomosis.
Information on intraoperative gross rectosigmoid lesions and residual tumors were 
retrospectively obtained from medical records. Optimal debulking surgery was defined as 
residual tumor ≤1.0 cm. Progression-free survival (PFS) was defined as the length of time 
from the date of primary staging surgery to the date of cancer recurrence or death from any 
cause. Women who were still alive without cancer recurrence at the time of the analysis were 
censored at the time of their last follow-up. Overall survival (OS) was defined as the length of 
time from the date of primary staging surgery to the date of death from any cause. Women 
who were still alive with/without the disease at the time of the analysis were censored at the 
time of their last follow-up. Operation-related morbidity, including ileus, bowel leakage, fever 
lasting 3 days postoperative, and wound dehiscence, was also evaluated in the study cohort. 
Aside from analysis in the whole study cohort (n=397), the same analysis was repeated in the 
cohort of patients who had rectosigmoid lesions infiltrating up to the muscle and mucosa, as 
recorded in the final pathologic reports were excluded to minimize the impact of the invasion 
depth of rectosigmoid lesions to survival outcomes (n=387).
2. Statistical analysis
Chi-squared test, Fisher's exact test, and Mann-Whitney U test were used to evaluate the 
dichotomous variables. Survival outcomes were compared using the Kaplan-Meier curves 
with log-rank test. Statistical analyses were performed using Statistical Package for the Social 
Sciences Version 22.0 (IBM Inc., Chicago, IL, USA). A p-value <0.05 was considered significant.
RESULTS
1. Patient characteristics
A total of 397 patients were eligible for our study cohort. Patient characteristics are 
summarized in Table 1. The median age was 51 years (range, 17–88), and the median follow-up 
period was 55 months (range, 1–260). Colonoscopy was performed in 200 (50.4%) patients 
before surgery. Ninety-two (23.2%) patients had gross rectosigmoid lesions that did not have 
intraoperative evidence of invasion up to the muscle or mucosa according to the surgeon's 
judgment. Of these patients, 24 (26.1%) received LAR, and the other 68 (73.9%) received only 
tumorectomy without bowel resection. In our cohort, all patients with rectosigmoid lesions 
underwent bowel surgery to avoid residual tumors, tumorectomy, or LAR, while no patients 
without rectosigmoid lesions underwent any bowel surgery. Optimal debulking with residual 
tumor less than 1.0 cm was achieved in 335 patients (84.4%). Unfortunately, the residual 
tumors of 52 (13.1%) patients were not described in their operation records. After surgery, a 
large portion of the population was confirmed as FIGO stage IIB (212, 53.4%). A total of 335 
patients (84.4%) received appropriate platinum-based adjuvant chemotherapy for 6 or more 
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cycles. A total of 141 patients (35.5%) had cancer recurrence, and 81 (20.4%) died at time of 
analysis. Five-year PFS rates were 64.9%, 60.8%, and 47.0% in FIGO stage IIA, IIB, and IIIA, 
respectively (p=0.136). Meanwhile, 5-year OS rates were 84.3%, 80.3%, and 80.6% in each 
stage (p=0.423) (Fig. 1).
The logistic regression analysis for independent risk factors of survival outcomes was 
performed and its results were presented in Table 2. In multivariate analysis, the disease 
stage was not associated with PFS (FIGO ≥IIB, hazard ratio [HR]=1.402; 95% confidence 
interval [CI]=0.881–2.230; p=0.052) in this study population. Residual tumor ≥0.5 cm was a 
sole independent risk factor for OS (HR=2.129; 95% CI=1.124–4.033; p=0.020).
2. Tumorectomy vs. LAR
Comparison of clinicopathologic characteristics according to the type of bowel surgery (no 
bowel surgery [n=305], tumorectomy [n=68], and LAR [n=24]) is shown in Table 3. Optimal 
debulking was achieved in almost all patients who underwent tumorectomy and LAR (67 
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Table 1. Patient characteristics (n=397)
Characteristics Value
Age (yr) 51 (17–88)
Follow-up period (mo) 55 (1–260)
Preoperative CA-125 (U/mL) 161.0 (3.1–31,600.0)
Preoperative colonoscopy
No 197 (49.6)
Yes 200 (50.4)
Rectosigmoid lesions
Absent 305 (76.8)
Present 92 (23.2)
Rectum 51
Sigmoid colon 13
Unknown* 28
Bowel surgery
No 305 (76.8)
Tumorectomy 68 (17.1)
LAR 24 (6.1)
Optimal debulking
No 10 (2.5)
Yes 335 (84.4)
Unknown* 52 (13.1)
Histologic type
Serous 209 (52.6)
Non-serous 188 (47.4)
FIGO stage
IIA 116 (29.2)
IIB 212 (53.4)
IIIA 69 (17.4)
Adjuvant chemotherapy (cycles) 6 (0–20)
Adjuvant chemotherapy ≥6 cycles
No 62 (15.6)
Yes 335 (84.4)
Recurrence
No 256 (64.5)
Yes 141 (35.5)
Death
No 316 (79.6)
Yes 81 (20.4)
Values are presented as number (%) or median (range).
CA-125, cancer antigen-125; FIGO, International Federation of Gynecology and Obstetrics; LAR, Low anterior resection.
*Without descriptions on operation records.
[98.5%] vs. 19 [95.0%], p=0.405). One patient (4.2%) who underwent LAR had residual 
tumor >1.0 cm after surgery. Non-serous histologic type was similarly detected between 
patients who underwent tumorectomy and LAR (32 [47.1%] vs. 12 [50.0%], p=0.804). Almost 
all patients who underwent tumorectomy were diagnosed as FIGO stage IIB after surgery (53, 
77.9%). FIGO stage IIIA was more frequent in patients who underwent LAR than in those 
who underwent tumorectomy (10 [41.7%] vs. 12 [17.7%], p=0.057) due to retroperitoneal 
lymph node metastasis or microscopic extra-pelvic peritoneal involvement. However, the 
frequency was not significantly different. Platinum-based adjuvant chemotherapy for 6 or 
more cycles was performed in almost all patients in both groups (58 [85.3%] vs. 19 [79.2%], 
p=0.485). The cohort excluding the patients who had rectosigmoid lesions infiltrating up 
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Fig. 1. (A) The 5-year PFS (64.9%, 60.8%, and 47.0%; p=0.136) and (B) 5-year OS (84.3%, 80.3%, and 80.6%; p=0.423) in the whole study population (n=397) 
(solid line: FIGO stage IIA; dotted line: FIGO stage IIB; and dot-and-dash line: FIGO stage IIIA). 
FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; PFS, progression-free survival.
Table 2. Univariate and multivariate analysis for independent risk factors of survival outcomes (n=397)
Characteristics Univariate Multivariate
HR (95% CI) p HR (95% CI) p
PFS
Age ≥51 yr 0.973 (0.645–1.468) 0.898
Presence of rectosigmoid lesion 1.085 (0.668–1.761) 0.742
Invasion depth of rectosigmoid lesion > subserosa 1.846 (0.525–6.487) 0.339
Bowel surgery (tumorectomy vs. LAR) 1.238 (0.465–3.297) 0.669
Residual tumor ≥0.5 cm 1.828 (1.029–3.249) 0.040 1.716 (0.960–3.066) 0.068
Residual tumor ≥1.0 cm 1.226 (0.339–4.431) 0.756
Histology of non-serous 1.259 (0.834–1.901) 0.272
FIGO stage ≥ IIB 1.402 (0.881–2.230) 0.154 1.664 (0.995–2.784) 0.052
FIGO stage ≥ IIIA 1.299 (0.763–2.211) 0.334
OS
Age ≥51 yr 1.206 (0.739–1.966) 0.454
Presence of rectosigmoid lesion 1.111 (0.629–1.963) 0.717
Invasion depth of rectosigmoid lesion > subserosa 2.684 (0.739–9.746) 0.133 3.261 (0.838–12.692) 0.088
Bowel surgery (tumorectomy vs. LAR) 1.286 (0.430–3.844) 0.653
Residual tumor ≥0.5 cm 2.145 (1.136–4.048) 0.019 2.129 (1.124–4.033) 0.020
Residual tumor ≥1.0 cm 1.000 (0.208–4.818) >0.999
Histology of non-serous 1.334 (0.818–2.177) 0.248
FIGO stage ≥ IIB 1.331 (0.761–2.328) 0.316
FIGO stage ≥ IIIA 1.103 (0.586–2.076) 0.762
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; LAR, low anterior resection; OS, overall survival; PFS, 
progression-free survival.
to the muscle and mucosa is described in Supplementary Table 1. FIGO stage between the 
patients treated with tumorectomy and LAR was significantly different (FIGO stage IIB, 12 
[17.9%] vs. 8 [53.3%], p=0.004).
Survival outcomes in patients who received bowel surgery for rectosigmoid lesions 
are presented in Fig. 2. The 5-year PFS was similar between patients who underwent 
tumorectomy and those who underwent LAR (57.9% vs. 62.5%, p=0.767). The 5-year OS of 
patients who underwent tumorectomy was superior to those treated with LAR; however, 
it was not significantly different (84.7% vs. 63.8%, p=0.087). These survival outcome 
findings coincided with those of the cohort in which patients who had rectosigmoid lesions 
infiltrating up to the muscle and mucosa were excluded (Supplementary Fig. 1; 5-year PFS, 
58.9% vs. 60.2%, p=0.994; 5-year OS, 90.1% vs. 66.7%, p=0.147).
3. No bowel surgery vs. tumorectomy
The rates of the optimal debulking (249 [96.9%] vs. 67 [98.5%], p=0.463) and non-serous 
histology (144 [47.2%] vs. 32 [47.1%], p=0.982) were not different between patients who 
did not undergo bowel surgery and who underwent tumorectomy. FIGO stage IIB was 
less frequent in patients who did not undergo any bowel surgery, compared to those of 
tumorectomy (145 [47.5%] vs. 53 [77.9%], p<0.001). In addition, adjuvant chemotherapy 
for 6 or more cycles was equally administered in both groups (258 [84.6%] vs. 58 [85.3%], 
p=0.884). Except for FIGO staging, no significant difference was noted in both groups 
after patients who had rectosigmoid lesions infiltrating up to the muscle and mucosa were 
excluded (Supplementary Table 1).
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Table 3. Comparisons of clinicopathologic factors (n=397)
Characteristics No bowel surgery 
(n=305)
Tumorectomy (n=68) LAR (n=24) p‡
Value p* Value p†
Age (yr) 52.0±11.5 52.8±11.4 0.618 54.5±12.7 0.552 0.567
Preoperative CA-125 (U/mL) 671.3±1,607.7 702.9±1,042.2 0.885 2,120.4±6,552.6 0.302 0.008
Location of rectosigmoid lesions¶ - - 0.759 -
Rectum 33 (78.6) 18 (81.8)
Sigmoid colon 9 (21.4) 4 (18.2)
Optimal debulking¶ 0.463 0.405 0.942
No 8 (3.1) 1 (1.5) 1 (5.0)
Yes 249 (96.9) 67 (98.5) 19 (95.0)
Histologic type 0.982 0.804 0.851
Serous 161 (52.8) 36 (52.9) 12 (50.0)
Non-serous 144 (47.2) 32 (47.1) 12 (50.0)
FIGO stage <0.001 0.057 <0.001
IIA 113 (37.0) 3 (4.4) 0
IIB 145 (47.5) 53 (77.9) 14 (58.3)
IIIA 47 (15.4) 12 (17.7) 10 (41.7)
Adjuvant chemotherapy (cycles) 5.8±1.8 5.9±1.6 0.760 5.5±2.5 0.568 0.774
Adjuvant chemotherapy ≥6 cycles 0.884 0.485 0.650
No 47 (15.4) 10 (14.7) 5 (20.8)
Yes 258 (84.6) 58 (85.3) 19 (79.2)
Recurrence 0.623 0.669 0.883
No 198 (64.9) 42 (61.8) 16 (66.7)
Yes 107 (35.1) 26 (38.2) 8 (33.3)
Death 0.913 0.652 0.612
No 244 (80.0) 54 (79.4) 18 (75.0)
Yes 61 (20.0) 14 (20.6) 6 (25.0)
Values are presented as number (%) or mean±standard deviations.
CA-125, Cancer antigen-125; FIGO, International Federation of Gynecology and Obstetrics; LAR, Low anterior resection.
*No bowel surgery vs. tumorectomy; †Tumorectomy vs. LAR; ‡Among 3 groups; ¶In patients with available data.
Survival outcomes in patients treated without bowel surgery and with tumorectomy are 
presented in Fig. 2. The 5-year PFS (60.3% vs. 57.9%, p=0.523) and 5-year OS (81.8% vs. 
87.7%, p=0.912) in patients who underwent tumorectomy were not inferior to those of 
the patients who had no rectosigmoid lesions primarily. These survival outcome findings 
coincided with those of the cohort in which patients who had rectosigmoid lesions 
infiltrating up to the muscle and mucosa were excluded (Supplementary Fig. 1; 5-year PFS, 
60.3% vs. 58.9%, p=0.632; 5-year OS, 81.2% vs. 90.1%, p=0.929).
4. Operation-related morbidity in patients treated with LAR
Operation-related outcomes and morbidity were presented in Table 4. Operation time was 
longer in patients with LAR than those without LAR (390.4±142.8 minutes vs. 232.7±80.6 
minutes; p<0.001). In addition, more intraoperative blood loss was estimated in patients 
with LAR (856.3±753.3 mL vs. 570.2±539.0 mL; p=0.015). Postoperative ileus was more 
common in patients who underwent LAR than those who did not (4 [16.7%] vs. 11 [2.9%], 
p=0.001). However, the incidences of bowel leakage, fever lasting more than 3 days 
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Fig. 2. (A) The 5-year PFS (57.9% vs. 62.5%, p=0.767) and (B) 5-year OS (84.7% vs. 63.8%, p=0.087) in patients who had rectosigmoid lesions (solid line: 
tumorectomy group [n=68]; dotted line: LAR group [n=24]). (C) The 5-year PFS (60.3% vs. 57.9%, p=0.523) and (B) 5-year OS (81.8% vs. 87.7%, p=0.912) in 
patients who did not receive LAR (solid line: no bowel surgery group [n=305]; dotted line: tumorectomy group [n=68]). 
LAR, low anterior resection; OS, overall survival; PFS, progression-free survival.
postoperative, and wound dehiscence associated to LAR were not different. LAR-related 
morbidity in the cohort excluding the patients who had rectosigmoid lesions infiltrating up 
to the muscle and mucosa is described in Supplementary Table 2. Postoperative ileus was 
also frequently diagnosed in patients treated with LAR (3 [20.0%] vs. 12 [3.0%], p=0.001).
DISCUSSION
Our findings suggested that the survival outcomes depending on the procedure type for 
the extirpation of rectosigmoid lesions, i.e., tumorectomy vs. LAR, were not statistically 
different. Although retroperitoneal lymph node micro-metastasis was frequent in patients 
who underwent LAR, our findings are meaningful when considering that no gross seeding 
tumor existed above the pelvic brim in all patients. Notably, the survival outcomes in patients 
with rectosigmoid lesions who underwent tumorectomy only were not inferior to those in 
patients who had no rectosigmoid lesions primarily. Furthermore, optimal debulking was 
similarly achieved between patients who underwent tumorectomy and those who underwent 
LAR (67 [98.5%] vs. 19 [95.0%], p=0.405). These results imply that the tumors on the 
rectosigmoid colon are relatively well-controlled without bowel resection. In this study, the 
increased operation-related morbidity following LAR, such as ileus, could also in no way be 
negligible (4 [16.7%] vs. 11 [2.9%], p=0.001).
The effect of the procedure type for bowel resection on survival outcomes in patients 
diagnosed with advanced EOC (FIGO stage III–IV) had been proven in several researches. 
Most studies suggested that rectosigmoid resection might help improve the survival 
outcomes in patients with advanced EOC with acceptable complication rate [7-13]. However, 
Jaeger et al. [14] demonstrated that bowel resection could not improve the poor prognosis of 
bowel involvement in 194 patients with FIGO stage III disease. In their study, patients without 
bowel involvement and no residual tumor after surgery showed a significantly better survival 
rate than other patients irrespective of the resection status. However, all previous studies that 
evaluated the survival impact of bowel resection were based on advanced-stage EOC. FIGO 
stage II consists of a small and heterogeneous group, making up less than 10% of all EOC; 
therefore, many issues in therapeutic management remain unresolved. We hope that our 
findings could help surgeons regarding the prognostic implication of the resectional base 
after tumorectomy for tumors on the rectosigmoid colon.
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Table 4. Operation-related outcomes and morbidity (n=397)
Characteristics No LAR (n=373) LAR (n=24) p
Operation time (min) 232.7±80.6 390.4±142.8 <0.001
Estimated blood loss (mL) 570.2±539.0 856.3±753.3 0.015
Ileus 0.001
No 362 (97.1) 20 (83.3)
Yes 11 (2.9) 4 (16.7)
Bowel leakage >0.999
No 372 (99.7) 24 (100.0)
Yes 1 (0.3) 0
Fever >3 days 0.519
No 365 (97.9) 23 (95.8)
Yes 8 (2.1) 1 (4.2)
Wound dehiscence 0.271
No 355 (95.2) 24 (100.0)
Yes 18 (4.8) 0
LAR, low anterior resection.
The major site of bowel resection is the rectosigmoid (48%–55%), followed by the rest of 
the colon (18%–20%) and the small bowel (6%–27%), depending on the studies [9,15,16]. 
As the most important prognostic factor for operation-related morbidity, the extent of 
bowel resection can also affect optimal debulking. Kim et al. [17] on comparing the efficacy 
between LAR and Hartmann's operation in advanced or recurrent EOC, suggested that 
LAR may be the optimal procedure for bowel surgery in these patients and may improve 
postoperative quality of life. Surgical and survival outcomes between LAR and Hartmann's 
operation did not differ. Similarly, Plotti et al. [18] compared the safety and efficacy of 
partial rectosigmoid resection (PRR) to those of Hartmann's operation in advanced EOC 
through a case-control study. In their study, the optimal debulking rate and 5-year OS was 
not statistically different between the 2 groups. However, in Hartmann's operation group, 
they observed 4 cases of rectovaginal fistula compared with only 2 cases in PRR. In addition, 
adjuvant chemotherapy lasted 24 (19–28) days and 18 (15–24) days in Hartmann's operation 
and PRR groups (p=0.05), respectively. To the best of our knowledge, our study is the first to 
report the impact of tumorectomy without bowel resection for affected rectosigmoid lesions 
in EOC survival outcomes and operation-related morbidity. In the present study, the survival 
outcomes in patients treated with tumorectomy were not inferior to those of the patients 
with LAR, if optimal debulking could be guaranteed. However, evidence for the safety of the 
tumorectomy or serosectomy on rectosigmoid colon is lacking, and a global guideline has yet 
to be established. Therefore, our results should be cautiously applied in clinical practice.
Our study also has several limitations due to its retrospective nature. First, the sample size 
of the LAR group is relatively small compared with that of the control. Second, we could not 
fully obtain information about intraoperative characteristics of rectosigmoid lesions due to 
limited description. Recently, the National Comprehensive Cancer Network recommended 
that for ovarian cancer, surgeons should describe the initial disease intimately, including that 
in the pelvis, mid-abdomen, and upper abdomen [19]. Finally, we did not analyze the impact 
of neoadjuvant chemotherapy (NAC) to LAR performance or survival outcomes. Philip et al. 
[20] reported that NAC resulted in decreased bowel resection, which is necessary to achieve 
optimal debulking in advance EOC. Before NAC, at least 84 patients (87%) would have 
required bowel resection to obtain optimal debulking without residual tumor. After interval 
debulking surgery, only 47 patients (49%) required bowel resection, which corresponds to a 
decrease of 38% (p<0.001).
In the present study, the survival benefit of LAR was not significant in EOC patients with 
grossly pelvis-confined tumors. Furthermore, postoperative ileus was frequently detected 
in patients treated with LAR. If rectosigmoid lesions can be resected without residual 
tumors via tumorectomy, then LAR seems to be not mandatory to improve prognosis in 
patients with grossly pelvis-confined EOC. Further large prospective studies are necessary 
to establish standard methods and the safety of tumorectomy or serosectomy to eliminate 
rectosigmoid lesions.
SUPPLEMENTARY MATERIALS
Supplementary Table 1
Comparisons of clinicopathologic factors (n=387)
Click here to view
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Supplementary Table 2
Operation-related outcomes and morbidity (n=387)
Click here to view
Supplementary Fig. 1
(A) The 5-year PFS (58.9% vs. 60.2%, p=0.994) and (B) 5-year OS (90.1% vs. 66.7%, p=0.147) 
in patients who had rectosigmoid lesions (solid line: tumorectomy group [n=67]; dotted line: 
LAR group [n=15]). (C) The 5-year PFS (60.3% vs. 58.9%, p=0.632) and (B) 5-year OS (81.2% 
vs. 90.1%, p=0.929) in patients who did not receive LAR (solid line: no bowel surgery group 
[n=305]; dotted line: tumorectomy group [n=67]).
Click here to view
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